Katherine Bowdish

Katherine (Kathy) Bowdish is a molecular geneticist and biopharmaceutical leader who serves as President and CEO of PIC Therapeutics, a Natick, Massachusetts biotech developing cancer drugs that work by modulating RNA translation - targeting the eIF4E 'master switch' that tumors use to overproduce oncogene proteins. Over more than two decades she has founded and led a string of early-stage life science companies including Prolifaron (acquired by Alexion), Anaphore and Permeon Biologics, and she built and ran Sanofi Sunrise, the pharma giant's early-stage venture and partnering arm. She holds a PhD in molecular genetics from Columbia and led PIC through a $35 million Series A to push its lead program toward the clinic in drug-resistant breast cancer.